epoetin alfa
- Generic Name
- epoetin alfa
The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery
Phase 4
Terminated
- Conditions
- Hemostasis, Surgical
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2013-07-22
- Target Recruit Count
- 37
- Registration Number
- NCT00350519
A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.
Phase 3
Completed
- Conditions
- ChemotherapyAnemiaCancer
- First Posted Date
- 2006-06-21
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 69
- Registration Number
- NCT00341055
EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure
Phase 4
Completed
- Conditions
- Chronic Renal Failure
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 292
- Registration Number
- NCT00338000
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks
Phase 2
Completed
- Conditions
- ChemotherapyAnemiaCancer
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 129
- Registration Number
- NCT00337948
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks
Phase 2
Completed
- Conditions
- CancerAnemia
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 115
- Registration Number
- NCT00338416
Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia
Phase 2
Completed
- Conditions
- AnemiaChemotherapy
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2011-05-23
- Target Recruit Count
- 51
- Registration Number
- NCT00338299
A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)
Phase 4
Terminated
- Conditions
- AnemiaKidney Diseases
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 13
- Registration Number
- NCT00338468
A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.
Phase 2
Completed
- Conditions
- Renal Failure , ChronicAnemia
- Interventions
- Other: Standard of care
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2013-05-13
- Target Recruit Count
- 157
- Registration Number
- NCT00337935
An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)
Phase 4
Completed
- Conditions
- AnemiaHIV Infections
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 292
- Registration Number
- NCT00317902
Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency
Phase 4
Terminated
- Conditions
- AnemiaRenal Failure, Chronic Renal Failure
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen Cilag S.A.S.
- Target Recruit Count
- 217
- Registration Number
- NCT00312871
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath